Table 6 Pim kinase inhibitors used in preclinical and clinical (bold) trials for cHL and NHL
From: Targeting Pim kinases in hematological cancers: molecular and clinical review
| Â | Pim Inhibitor | Target | Type | Clinical Trials | Â |
|---|---|---|---|---|---|
cHL | SEL24/MEN1703 | PIM/FLT3 | Double inhibitor (FLT3, Pim) Monotherapy | Yes | – |
Pim Inhibitor + suberoylanilide hydroxamic acid (SAHA) or sodium butyrate (SB | Pim + Histone deacetylase inhibitors | Dual-therapy | Preclinical | – | |
DLBCL | AZD1208 + ibrutinib | pan-Pim + BTK | Dual-therapy | Preclinical | – |
ETH-155008 | Pim3-CDK4/6(FLT3) | Triple inhibitor (FLT3, Pim-3 and CDK4/6) Monotherapy | DLBCL | NCT04840784 | |
Uzansertib | pan-Pim | Single | DLBCL | NCT03688152 | |
Uzansertib + Parsaclisib | pan-Pim + PI3K | Dual-therapy | DLBCL | Incyte | |
Uzansertib + Itacitinib (or ruxolitinib) | pan-Pim + JAK | Dual-therapy | Preclinical | – | |
Uzansertib + cytarabine | pan-Pim + Chemotherapy | Dual-therapy | Preclinical | – | |
PTCL | ETP-39010 | pan-Pim | Single | Preclinical | – |
ETP-47551 | pan-Pim | Single | Preclinical | – | |
MCL | SGI-1776 | PIM1 | Single | MCL | NCT01239108 |
CLL/SLL | K00135 | Pim1/Pim2 | Single | Preclinical | – |
K00486 | Pim1/Pim2 | Single | Preclinical | – | |
A47 | pan-Pim | Single | Preclinical | – | |
ETH-155008 | Pim3-CDK4/6 (FLT3) | Triple inhibitor (FLT3, Pim-3 and CDK4/6) Monotherapy | CLL/SLL | NCT04840784 | |
SGI-1776 | PIM1 | Single | Yes | – | |
SEL24/MEN1703 | PIM/FLT3 | Double inhibitor (FLT3, Pim) Monotherapy | Yes | – | |
LGB321 | pan-Pim | Single | Preclinical | – | |
LGB321 + ibrutinib | pan-Pim + BTK | Dual-therapy | Preclinical | – | |
ATL | Smi-16a | Pim1/Pim2 | Single | Preclinical | – |
AZD1208 | pan-Pim | Single | Yes | – |